

# UpToDate

**R.Kousari**

**M.Sc in Medical Library & Information science**

**Head Of The Central Library Of DUMS**

# Introduction of the Database



## Content:

- ❖ More than 10500 Medical Topics
- ❖ More than 5400 Drug Information
- ❖ More than 1900 Patient Topic or Patient Education
- ❖ More than 28000 Graphics
- ❖ More than 160000 Medical Calculators

## Also

- ❖ Collaborating with more than 6000 authors in world wide
- ❖ More than 400000 links to valid references
- ❖ covering more than 25 specialty

&

- ❖ Who are the authors?
- ❖ Is this really uptodate?

# How to connect to the Database?

❖ It's IP Based    OR

❖ Use VPN

❖ URL: www.UpToDate.com    OR

❖ Use: <http://diglib.dums.ac.ir/>

What's New

Practice Changing UpDates

Drug Information

Patient Education

Topics by Specialty

Authors and Editors

Search UpToDate



# How to use the Database?

❖ smart indexing

❖ Don't use operators

UpToDate®

University of Medical Sciences ▾

Contents ▾

Calculators

Drug Interactions

Register

Log In

Search UpToDate

malignant |

- malignant hyperthermia
- malignant otitis externa
- malignant hypertension
- malignant melanoma

# Medical Topics

UpToDate®

malignant carcinoid



University of Medical Sciences ▾

Contents ▾ Calculators Drug Interactions

Register

Log In

< Back to Search

malignant carcinoid

Find

Print

Share



## Topic Outline

SUMMARY AND RECOMMENDATIONS

INTRODUCTION

SOMATOSTATIN-ANALOG THERAPY

Antiproliferative effects

LIVER-DIRECTED THERAPIES

MANAGEMENT OF REFRACTORY

SYMPTOMS

Telotristat

Interferon

## Treatment of the carcinoid syndrome

Author: [Jonathan R Strosberg, MD](#)

Section Editors: [Kenneth K Tanabe, MD](#), [David C Whitcomb, MD, PhD](#)

Deputy Editor: [Diane MF Savarese, MD](#)

[Contributor Disclosures](#)

All topics are updated as new evidence becomes available and our [peer review process](#) is complete.

Literature review current through: **Nov 2019**. | This topic last updated: **Jul 09, 2019**.

## INTRODUCTION

Carcinoid tumors are neuroendocrine tumors (NETs) that originate in the digestive tract, lungs, or rare primary sites, such as kidneys or ovaries. The term "carcinoid" usually

Topic Feedback

# • Grading system



malignant carcinoid



Menu

[< Back to Search](#) **Metastatic well-differentiated gastrointestin...**

malignant carcinoid

Find

[Print](#) [Share](#) 

Topic Outline

SUMMARY AND RECOMMENDATIONS

INTRODUCTION

CLASSIFICATION, BIOLOGIC BEHAVIOR,  
AND IMPLICATIONS FOR TREATMENT

GENERAL APPROACH TO THE PATIENT

SOMATOSTATIN ANALOGS

Patients with symptoms from hormone hypersecretion

- Dosing
- Side effects
- Prevention and management of carcinoid crisis

## SUMMARY AND RECOMMENDATIONS

### Initial therapy

- Somatostatin analogs are highly effective in controlling the symptoms associated with advanced gastrointestinal neuroendocrine tumors (GINETs). For patients who are symptomatic from carcinoid syndrome, we recommend initiating treatment with a somatostatin analog alone rather than a combination of a somatostatin analog and interferon alfa (IFNa) (**Grade 1B**). (See '[Somatostatin analogs](#)' above and '[Interferon](#)' above.)
- We also suggest initiating therapy with a somatostatin analog for patients who do not have carcinoid syndrome but who have somatostatin-receptor-positive disease (as determined by diagnostic imaging with a radiolabeled somatostatin analog) and a high tumor burden (**Grade 2B**). (See "[Metastatic well-differentiated gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging,](#)

Topic Feedback

---

## **Recommendation grades**

1. Strong recommendation: Benefits clearly outweigh the risks and burdens (or vice versa) for most, if not all, patients
2. Weak recommendation: Benefits and risks closely balanced and/or uncertain

## **Evidence grades**

- A. High-quality evidence: Consistent evidence from randomized trials, or overwhelming evidence of some other form
- B. Moderate-quality evidence: Evidence from randomized trials with important limitations, or very strong evidence of some other form
- C. Low-quality evidence: Evidence from observational studies, unsystematic clinical observations, or from randomized trials with serious flaws

For a complete description of our grading system, please see the UpToDate editorial policy.

---

---

# Drug information & Lexicomp database

[Contents](#) ▾[Calculators](#)[Drug Interactions](#)[Register](#)[Log In](#)

## Drug Information

You receive the entire UpToDate library of specialties with your subscription. Click on a section below to view a detailed list of topics associated with that particular section. If you'd like to see the table of contents for other specialties, [click here](#).

[General drug information](#)[Patient drug information](#)[What's new in drug therapy](#)[International drug information \(concise\)](#)[Pediatric drug information](#)[Patient Education](#)

## Topic Outline

Brand Names: US

Pharmacologic Category

Dosing: Adult

Dosing: Renal Impairment: Adult

Dosing: Hepatic Impairment: Adult

Dosing: Pediatric

Dosing: Renal Impairment: Pediatric

Dosing: Hepatic Impairment: Pediatric

# lobenguane I-131 (therapeutic): Drug information

Lexicomp®

[Access Lexicomp Online here.](#)

Copyright 1978-2019 Lexicomp, Inc. All rights reserved.

(For additional information [see "lobenguane I-131 \(therapeutic\): Patient drug information"](#) and [see "lobenguane I-131 \(therapeutic\): Pediatric drug information"](#))

For abbreviations and symbols that may be used in Lexicomp ([show table](#))

## Brand Names: US

Azedra Dosimetric; Azedra Therapeutic

## Pharmacologic Category

Radiopharmaceutical

# Drug interactions



Lexicomp® Drug Interactions

Add items to your list by searching below.

ITEM LIST

Clear List

Analyze

–

Ginseng\_(American)

–

Aldactone

Display complete list of interactions for an individual item by clicking item name.

Lexicomp® Drug Interactions

|          |                               |          |                  |                                  |                      |
|----------|-------------------------------|----------|------------------|----------------------------------|----------------------|
| <b>X</b> | Avoid combination             | <b>C</b> | Monitor therapy  | <b>A</b>                         | No known interaction |
| <b>D</b> | Consider therapy modification | <b>B</b> | No action needed | <i>More about Risk Ratings</i> ▼ |                      |

1 Result

Filter Results by Item ▼

Print

**C**

Aldactone (Antihypertensive Agents)  
Ginseng (American) (Herbs (Hypertensive Properties))

**DISCLAIMER:** Readers are advised that decisions regarding drug therapy must be based on the independent judgment of the clinician, changing information about a drug (eg, as reflected in the literature and manufacturer's most current product information), and changing medical practices.

|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|---|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| X | <p><b>Avoid Combination</b></p> <p>Data demonstrate that the specified agents may interact with each other in a clinically significant manner. The risks associated with concomitant use of these agents usually outweigh the benefits. These agents are generally considered contraindicated.</p>                                                                                                                                                                                                                                          |
| D | <p><b>Consider Therapy Modification</b></p> <p>Data demonstrate that the two medications may interact with each other in a clinically significant manner. A patient-specific assessment must be conducted to determine whether the benefits of concomitant therapy outweigh the risks. Specific actions must be taken in order to realize the benefits and/or minimize the toxicity resulting from concomitant use of the agents. These actions may include aggressive monitoring, empiric dosage changes, choosing alternative agents.</p> |
| C | <p><b>Monitor Therapy</b></p> <p>Data demonstrate that the specified agents may interact with each other in a clinically significant manner. The benefits of concomitant use of these two medications usually outweigh the risks. An appropriate monitoring plan should be implemented to identify potential negative effects. Dosage adjustments of one or both agents may be needed in a minority of patients.</p>                                                                                                                        |
| B | <p><b>No Action Needed</b></p> <p>Data demonstrate that the specified agents may interact with each other, but there is little to no evidence of clinical concern resulting from their concomitant use.</p>                                                                                                                                                                                                                                                                                                                                 |
| A | <p><b>No Known Interaction</b></p> <p>Data have not demonstrated either pharmacodynamic or pharmacokinetic interactions between the specified agents</p>                                                                                                                                                                                                                                                                                                                                                                                    |

# Graphics

UpToDate®

malignant carcinoid



University of Medical Sciences ▾

Contents ▾ Calculators Drug Interactions

Register

Log In

Showing results for **malignant carcinoid**

All

Adult

Pediatric

Patient

Graphics

Click on what you meant by carcinoid: [carcinoid syndrome](#), [carcinoid tumor](#)



Evaluation and treatment of malignancy-related ascites




Malignant tracheoesophageal fistula\*





Treatment algorithm for malignant pheochromocytoma and



Algorithmic approach to diagnosis and management of



Initial treatment of malignant glioma in older adults



# Calculators

UpToDate®



University of Medical Sciences ▾

Contents ▾

Calculators

Drug Interactions

Register

Log In

## Calculators

View By Specialty

List Alphabetically

bmi

### ANESTHESIOLOGY CALCULATORS

Medical Equations

Body mass index (BMI; Quetelet's index) in adults

### DERMATOLOGY CALCULATORS

Medical Equations

## Calculator: Body mass index (BMI; Quetelet's index) in adults

$$\text{BMI} = (\text{Weight}/2.205) / (\text{Height}/39.37)^2$$

**Input:**

|        |                      |      |
|--------|----------------------|------|
| Height | <input type="text"/> | in ▾ |
| Weight | <input type="text"/> | lb ▾ |

**Result:**BMI  kg/m<sup>2</sup>Decimal precision  ▾

Reset form

## BMI interpretation

# Patient education

[Contents](#) ▾ [Calculators](#) [Drug Interactions](#)

[Register](#)

[Log In](#)

## Patient Education

### Patient Education

UpToDate offers two levels of content for patients:

- **The Basics** are short overviews. They are written in accordance with plain language principles and answer the four or five most important questions a person might have about a medical problem.
- **Beyond the Basics** are longer, more detailed reviews. They are best for readers who want detailed information and are comfortable with some medical terminology.

[Learn more](#) about UpToDate's patient education materials.



This site complies with the [HONcode standard](#) for trustworthy health information: [verify here](#).

To browse the available patient education topics in UpToDate, click on a category below.

[Allergies and asthma](#)

[Arthritis](#)

[Autoimmune disease](#)

[Blood disorders](#)

[Bones, joints, and muscles](#)

[Brain and nerves](#)

[Cancer](#)

[Children's health](#)

[Diabetes](#)

[Ear, nose, and throat](#)

[Eyes and vision](#)

[Gastrointestinal system](#)

[General health](#)

[Heart and blood vessel disease](#)

[HIV and AIDS](#)

[Hormones](#)

[Infections and vaccines](#)

[Kidneys and urinary system](#)

[Lung disease](#)

[Men's health issues](#)

[Mental health](#)

[Pregnancy and childbirth](#)

[Senior health](#)

[Skin, hair, and nails](#)

[Sleep](#)

[Surgery](#)

[Travel health](#)

## Topic Outline

[What is a blocked tear duct?](#)[What are the symptoms of a blocked tear duct?](#)[Will my child need tests?](#)[How is a blocked tear duct treated?](#)[More on this topic](#)

## GRAPHICS

[view all](#)

## Figures

- [Tear duct system](#)

## RELATED TOPICS

[Patient education: Conjunctivitis \(pink eye\)  
\(Beyond the Basics\)](#)

## Patient education: Blocked tear duct (The Basics)

[View in \[Spanish\]\(#\)](#)[Written by the doctors and editors at UpToDate](#)

### What is a blocked tear duct?

A blocked tear duct is a condition that causes the eyes to tear much more than usual. The tear duct is how tears drain from the eye. It is a path of small tubes that runs from the inner eyelid to the inside of the nose ([figure 1](#)). If the tear duct is blocked, tears can't drain normally. This causes symptoms.

A blocked tear duct is a common condition in babies. Babies who have a blocked tear duct are usually born with it.

Older children and adults can also get a blocked tear duct. The cause of the blockage is usually an eye infection or injury.

### What are the symptoms of a blocked tear duct?

# Practice Changing UpDates

Contents ▾ Calculators Drug Interactions

Register

Log In

Find

Print

Share



## Topic Outline

### INTRODUCTION

### PEDIATRICS (November 2019)

Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis caused by the F508del variant

### HEMATOLOGY (November 2019)

Lenalidomide for high-risk smoldering multiple myeloma

### CARDIOVASCULAR MEDICINE (October 2019)

Dapagliflozin for heart failure with reduced ejection fraction

### OBSTETRICS, GYNECOLOGY AND WOMEN'S HEALTH (August 2019)

New ACOG guidelines for preventing early-onset group B streptococcus infection in newborns

### HEMATOLOGY (December 2018, Modified August 2019)

## Practice Changing UpDates

**Authors:** [H Nancy Sokol, MD](#), [April F Eichler, MD, MPH](#)

[Contributor Disclosures](#)

All topics are updated as new evidence becomes available and our [peer review process](#) is complete.

Literature review current through: **Nov 2019**. | This topic last updated: **Dec 03, 2019**.

## INTRODUCTION

This section highlights selected specific new recommendations and/or updates that we anticipate may change usual clinical practice. Practice Changing UpDates focus on changes that may have significant and broad impact on practice, and therefore do not represent all updates that affect practice. These Practice Changing UpDates, reflecting important changes to UpToDate over the past year, are presented chronologically, and are discussed in greater detail in the identified topic reviews.

## PEDIATRICS (November 2019)

### Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis caused by the F508del variant

- For patients age  $\geq 12$  years old with cystic fibrosis who are homozygous for the F508del variant, we suggest a triple therapy regimen ([elexacaftor-tezacaftor-ivacaftor](#)) rather than dual therapy ([tezacaftor-ivacaftor](#) or [lumacaftor-ivacaftor](#)) (**Grade 2B**). For patients  $\geq 12$  years who have one F508del variant(heterozygotes), we suggest the triple therapy regimen rather than dual therapy or monotherapy with

# What's New

[Contents](#) ▾[Calculators](#)[Drug Interactions](#)[Register](#)[Log In](#)

## What's New

Our editors select a small number of the most important updates and share them with you via What's New. See these updates by clicking on the specialty you are interested in below. You may also enter "What's new" in the search box.

### Find Out What's New In:

[Practice Changing UpDates](#)[Allergy and immunology](#)[Anesthesiology](#)[Cardiovascular medicine](#)[Dermatology](#)[Drug therapy](#)[Emergency medicine](#)[Endocrinology and diabetes mellitus](#)[Family medicine](#)[Gastroenterology and hepatology](#)[General surgery](#)[Geriatrics](#)[Hematology](#)[Hospital medicine](#)[Infectious diseases](#)[Nephrology and hypertension](#)[Neurology](#)[Obstetrics and gynecology](#)[Oncology](#)[Palliative care](#)[Pediatrics](#)[Primary care](#)[Psychiatry](#)[Pulmonary and critical care medicine](#)[Rheumatology](#)[Sleep medicine](#)[Sports medicine \(primary care\)](#)

If you have any questions, email the library:

**Diglib.dums@gmail.com**